Circulating Matrix Metalloproteinase 3 due to Myocardial Ischemia
Background: Experimental data suggest that matrix metalloproteinases (MMPs) such as MMP-3 have a central role in the remodeling period after a myocardial infarction (MI). The aim of this study was to use an experimental small-animal model to investigate the fluctuation in MMP-3 levels occurring in vivo after an acute MI.
Methods: We studied 13 New Zealand white rabbits weighing between 3 and 4 kg. After anesthetizing the animals, we performed a tracheotomy and induced an acute MI in 10 of the animals by occluding the left anterior descending coronary artery for 45 minutes. The remaining 3 rabbits constituted the control group. Three hours after reperfusion, blood samples were taken for biomedical analyses.
Results: Three hours after the artificially induced acute MI, serum MMP-3 levels were decreased by almost 50%. Cardiac troponin I (cTnI) concentrations were increased greatly (90-fold) after MI, further validating the efficiency of our experimental in vivo model of acute MI.
Conclusion: Combining the data, we demonstrated that acute MI caused an early reduction in MMP-3 levels. The range of MMP-3 reduction is limited compared with other factors predicting MI, such as cTnI, which increases its usefulness. We demonstrated, however, that plasma fluctuation in MMP-3 levels could be used as a supplementary independent predictor of cardiovascular events in patients with stable coronary artery disease. This acute MI model used in our controlled setting proved to be a reliable and safe method for conducting in vivo studies.
Abbott Laboratories. 1997. Abbott AXSYM System. Abbott Park, IL: Abbott Laboratories.nAbbott Laboratories. 2001. AxSYM System Operation Manual. Abbott Park, IL: Abbott Laboratories.nArdelt P, Dorka P, Jaquet K, et al. 1998. Microanalysis and distribution of cardiac troponin I phospho species in heart areas. Biol Chem 379:341-7.nBers DM. 2002. Cardiac Na/Ca exchange function in rabbit, mouse and man: What's the difference? J Mol Cell Cardiol 34:369-73.nBoyett MR, Jewell BR. 1978. A study of the factors responsible for rate-dependent shortening of the action potential in mammalian ventricular muscle. J Physiol 285:359-80.nCommittee on Care and Use of Laboratory Animals. 1996. Guide for the care and use of laboratory animals. US Dept. of Health and Human Services Publ. No. 85-23. Bethesda, MD: National Institutes of Health.nGreemers EE, Cleutjens JP, Smits JF, Daemen MJ. 2001. Matrix metalloproteinase inhibition after myocardial infarction: review. Circ Res 89:201-10.nIliodromitis EK, Kremastinos DT, Katritsis DG, Papadopoulos CC, Hearse DJ. 1997. Multiple cycles of preconditioning cause loss of protection in open-chest rabbits. J Mol Cell Cardiol 29:915-20.nLindsey ML, Gannon J, Aikawa M, et al. 2002. Selective matrix metalloproteinase inhibition reduces left ventricular remodeling but does not inhibit angiogenesis after myocardial infarction. Circulation 105:753-8.nLorell BH, Isoyama S, Grice WN, Weinberg EO, Apstein CS. 1988. Effects of ouabain and isoproterenol on left ventricular diastolic function during low-flow ischemia in isolated, blood-perfused rabbit hearts. Circ Res 63:457-67.nLu L, Gunja-Smith Z, Woessner JF, et al. 2000. Matrix metalloproteinases and collagen ultrastructure in moderate myocardial ischemia and reperfusion in vivo. Am J Physiol Heart Circ Physiol 279:601-9.nMarian AJ, Wu Y, Lim DS, et al. 1999. A transgenic rabbit model for human hypertrophic cardiomyopathy. J Clin Invest 104:1683-92.nOgata Y, Enghild JJ, Nagase H. 1992. Matrix metalloproteinase 3 (stromelysin) activates the precursor for the human matrix metalloproteinase 9. J Biol Chem 267:3581-4.nOkada Y, Takeuchi N, Tomita K, Nakanishi I, Nagase H. 1989. Immunolocalization of MMP-3 (stromelysin) in rheumatoid synovioblasts (B cells): correlation with rheumatoid arthritis. Ann Rheum Dis 48:645-53.nOkubo N, Hombrouck C, Fomes P, et al. 2000. Cardiac troponin I and myocardial contusion in the rabbit. Anesthesiology 93:811-7.nRomanic AM, Burns-Kurtis CL, Gout B, Berrebi-Bertrand I, Ohlstein EH. 2001. Matrix metalloproteinase expression in cardiac myocytes following myocardial infarction in the rabbit. Life Sci 68:799-814.nSamnegard A, Silveria A, Tornvall P, Hamsten A, Ericsson CG, Eriksson P. 2006. Lower serum concentration of matrix metalloproteinase-3 in the acute stage of myocardial infarction. J Intern Med 259:530-6.nSanbe A, James J, Tuzcu V, et al. 2005. Transgenic rabbit model for human troponin I-based hypertrophic cardiomyopathy. Circulation 111:2330-8.nSpinale FG. 2002. Matrix metalloproteinases: regulation and dysregulation in the failing heart [review]. Circ Res 90:520-30.nWu TC, Leu HB, Lin WT, Lin CP, Lin SJ, Chen JW. 2005. Plasma MMP-3 level is an independent prognostic factor in stable coronary artery disease. Eur J Clin Invest 35:537-45.nYellon DM, Iliodromitis E, Latchman DS, et al. 1992. Whole body stress fails to limit infarct size in the reperfused rabbit heart. Cardiovasc Res 26:342-6.n
How to Cite
Author Disclosure & Copyright Transfer Agreement
In order to publish the original work of another person(s), The Heart Surgery Forum® must receive an acknowledgment of the Author Agreement and Copyright Transfer Statement transferring to Forum Multimedia Publishing, L.L.C., a subsidiary of Carden Jennings Publishing Co., Ltd. the exclusive rights to print and distribute the author(s) work in all media forms. Failure to check Copyright Transfer agreement box below will delay publication of the manuscript.
A current form follows:
The author(s) hereby transfer(s), assign(s), or otherwise convey(s) all copyright ownership of the manuscript submitted to Forum Multimedia Publishing, LLC (Publisher). The copyright transfer covers the exclusive rights to reproduce and distribute the article and the material contained therein throughout the world in all languages and in all media of expression now known or later developed, including but not limited to reprints, photographic reproduction, microfilm, electronic data processing (including programming, storage, and transmission to other electronic data record(s), or any other reproductions of similar nature), and translations.
However, Publisher grants back to the author(s) the following:
- The right to make and distribute copies of all or part of this work for use of the author(s) in teaching;
- The right to use, after publication in The Heart Surgery Forum, all or part of the material from this work in a book by the author(s), or in a collection of work by the author(s);
- The royalty-free right to make copies of this work for internal distribution within the institution/company that employs the author(s) subject to the provisions below for a work-made-for-hire;
- The right to use figures and tables from this work, and up to 250 words of text, for any purpose;
- The right to make oral presentations of material from this work.
Publisher reserves the right to grant or refuse permission to third parties to republish all or part of the article or translations thereof. To republish, such third parties must obtain written permission from the Publisher. (This is in accordance with the Copyright Statute, United States Code, Title 17. Exception: If all authors were bona fide officers or employees of the U.S. Government at the time the paper was prepared, the work is a “work of the US Government” (prepared by an officer or employee of the US Government as part of official duties), and therefore is not subject to US copyright; such exception should be indicated on signature lines. If this work was prepared under US Government contract or grant, the US Government may reproduce, royalty-free, all or portions of this work and may authorize others to do so, for official US Government purposes only, if the US Government contract or grant so requires.
I have participated in the conception and design of this work and in the writing of the manuscript and take public responsibility for it. Neither this manuscript nor one with substantially similar content under my authorship has been published, has been submitted for publication elsewhere, or will be submitted for publication elsewhere while under consideration by The Heart Surgery Forum, except as described in an attachment. I have reviewed this manuscript (original version) and approve its submission. If I am listed above as corresponding author, I will provide all authors with information regarding this manuscript and will obtain their approval before submitting any revision. I attest to the validity, accuracy, and legitimacy of the content of the manuscript and understand that Publisher assumes no responsibility for the validity, accuracy, and legitimacy of its content. I warrant that this manuscript is original with me and that I have full power to make this Agreement. I warrant that it contains no matter that is libelous or otherwise unlawful or that invades individual privacy or infringes any copyright or other proprietary right. I agree to indemnify and hold Publisher harmless of and from any claim made against Publisher that relates to or arises out of the publication of the manuscript and agree that this indemnification shall include payment of all costs and expenses relating to the defense of any such claim, including all reasonable attorney’s fees.
I warrant that I have no financial interest in the drugs, devices, or procedures described in the manuscript (except as disclosed in the attached statement).
I state that the institutional Human Subjects Committee and/or the Ethics Committee approved the clinical protocol reported in this manuscript for the use of experimental techniques, drugs, or devices in human subjects and appropriate informed consent documents were utilized.
Furthermore, I state that any and all animals used for experimental purposes received humane care in USDA registered facilities in compliance with the “Principles of Laboratory Animal Care” formulated by the National Society for Medical Research and the “Guide for the Care and Use of Laboratory Animals” prepared by the Institute of Laboratory Animal Resources and published by the National Institutes of Health (NIH Publication No. 85-23, revised 1985).